Rifaximin Side Effects
Some side effects of rifaximin may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to rifaximin: oral tablet
Get emergency medical help if you have any of these signs of an allergic reaction while taking rifaximin: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using rifaximin and call your doctor at once if you have a fever or diarrhea that is watery or bloody.
Less serious side effects are more likely, and may include:
bloating, gas, stomach pain;
feeling like you need to empty your bowel urgently;
feeling like your bowel is not completely empty;
nausea, vomiting, constipation;
tired feeling; or
swelling in your hands, feet, or torso.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to rifaximin: oral tablet
Gastrointestinal side effects have included nausea (up to 14%), flatulence (11%), abdominal pain (up to 9%), abdominal distension (up to 8%), rectal tenesmus (7%), upper abdominal pain (6%), defecation urgency (6%), constipation (up to 6%), stomach discomfort (less than 5%), and vomiting (2%). Lower abdominal pain, abdominal tenderness, dry mouth, and esophageal variceal bleed have been reported in greater than 2% but less than 5% of patients. Diarrhea, blood in stool, dry throat, dysentery, fecal abnormality, gingival disorder, inguinal hernia, and dry lips have been reported in less than 2% of patients. Straining and bad taste in mouth have also been reported. Clostridium difficile associated colitis has been reported during postmarketing experience.
Other side effects have included peripheral edema (15%), fatigue (up to 12%), ascites (11%), back pain (6%), pyrexia (up to 6%), chest pain (less than 5%), and pain (less than 5%). Generalized edema, influenza-like illness, contusion, fall, and procedural pain have been reported in greater than 2% but less than 5% of patients. Ear pain, motion sickness, malaise, and hot flashes have been reported in less than 2% of patients.
Nervous system side effects have included dizziness (up to 13%) and headache (10%). Vertigo, amnesia, disturbance in attention, hypoesthesia, memory impairment, and tremor have been reported in greater than 2% but less than 5% of patients. Migraine, syncope, tinnitus, and loss of taste have been reported in less than 2% of patients.
Hypersensitivity side effects have included exfoliative dermatitis, rash, angioneurotic edema (swelling of face and tongue and difficulty swallowing), urticaria, pruritus, flushing, and anaphylaxis during postmarketing experience and have occurred as early as within 15 minutes of rifaximin administration.
Dermatologic side effects have included pruritus (up to 9%), rash (up to 5%), and cellulitis (greater than 2% but less than 5%). Clamminess, sunburn, and increased sweating have been reported in less than 2% of patients.
Musculoskeletal side effects have included muscle spasms (up to 9%), arthralgia (up to 6%), myalgia (less than 5%), and pain in extremity (greater than 2% but less than 5%). Neck pain and weakness have been reported in less than 2% of patients.
Hematologic side effects have included anemia (8%). Lymphocytosis, monocytosis, and neutropenia have been reported in less than 2% of patients.
Respiratory side effects have included cough (7%), nasopharyngitis (up to 7%), dyspnea (up to 6%), upper respiratory tract infection (less than 5%), and rhinitis (less than 5%). Pneumonia and epistaxis have been reported in greater than 2% but less than 5% of patients. Respiratory tract infection, nasal passage irritation, pharyngitis, pharyngolaryngeal pain, and rhinorrhea have been reported in less than 2% of patients.
Psychiatric side effects have included depression (7%), insomnia (up to 7%), confusional state (greater than 2% but less than 5%), and abnormal dreams (less than 2%).
Metabolic side effects have included increased weight (greater than 2% but less than 5%), anorexia (less than 5%), and dehydration (less than 5%). Hyperglycemia, hyperkalemia, hypoglycemia, and hyponatremia have been reported in greater than 2% but less than 5% of patients. Decreased weight has been reported in less than 2% of patients.
Genitourinary side effects have included choluria, dysuria, hematuria, polyuria, proteinuria, urinary frequency, and blood in urine in less than 2% of patients.
Cardiovascular side effects have included hypotension (greater than 2% but less than 5%).
Hepatic side effects have included increased aspartate aminotransferase in less than 2% of patients.
More rifaximin resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.